PDL BioPharma CEO John McLaughlin's 2018 pay rises 20% to $4.1M
PDL BioPharma reports 2018 executive compensation
By ExecPay News
Published: April 30, 2019
PDL BioPharma reported fiscal year 2018 executive compensation information on April 30, 2019.
In 2018, five executives at PDL BioPharma received on average a compensation package of $2.3M, a 12% increase compared to previous year.
Average pay of disclosed executives at PDL BioPharma
John P. McLaughlin, Chief Executive Officer, received $4.1M in total, which increased by 20% compared to 2017. 52% of McLaughlin's compensation, or $2.1M, was in option awards. McLaughlin also received $1.2M in non-equity incentive plan, $700K in salary, as well as $71K in other compensation.
Dominique Monnet, Chief Executive Officer, received a compensation package of $2.5M, which increased by 4% compared to previous year. 63% of the compensation package, or $1.6M, was in option awards.
Christopher Stone, General Counsel, earned $2.1M in 2018, a 55% increase compared to previous year.
Peter Garcia, Chief Financial Officer, received $2.1M in 2018, which increases by 53% compared to 2017.
Jill Jene, Vice President, Business Development, earned $771K in 2018.
Related executives
You may also like
Source: SEC filing on April 30, 2019.